CDKN2A and neoplasm: Many efforts have been made to understand the regulation mechanisms underlying p16INK4a expression location within the tumor cells and its possible therapeutic value by re-locating the dislocated p16INK4a to the optimal subcellular site in the malignancy [25-27].